FR TK inhibitors became resistant from a single mutation of the protein 1790M within the EGFR kinasc domain. PED's work caught the attention of Dr. Ben Vogelstein. the Director of the Ludwig Ccntcr for Cancer Genetics and Therapeutics at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University